Previous 10 | Next 10 |
Over the past few days, there have been some monster moves across a number of Russell 3,000 stocks. Taking a look at the Russell 3,000 members that had at least been cut in half from the time of the index’s high on January 3rd through the low on June 16th, followed by a rally o...
Recent clinical trial momentum has started to inflect positive on the chart for Kezar Life Sciences. The stock has caught a bid in June whilst reducing equity beta to the broad sector, illustrating the sensitivity of its idiosyncratic risk premia. We've also identified a potential...
Kezar Life Sciences ( NASDAQ: KZR ) has announced the appointment of Nick Mordwinkin, Pharm.D., Ph.D., as Chief Business Officer . Dr. Mordwinkin will be key to the next stage of Kezar’s growth and will be responsible for shaping the company’s business develo...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Nick Mordwinkin, Pharm.D., Ph.D., as Chief Business Officer. Dr. Mordwin...
Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate in a panel calle...
Gainers: Endo International plc (ENDP) +95%. Agile Therapeutics (AGRX) +66%. Kezar Life Sciences (KZR) +53%. Decibel Therapeutics (DBTX) +25%. Ceragon Networks (CRNT) +23%. InflaRx (IFRX) +20%. Sutro Biopharma (STRO) +19%. Tyra Biosciences (TYRA) +17%. Oasis Petroleum (OAS) +16%. Biotricity (...
Shares of the clinical-stage biotech Kezar Life Sciences (NASDAQ: KZR) are soaring this morning following a positive mid-stage data readout for its lupus nephritis candidate zetomipzomib. Specifically, the drugmaker's shares were up by an eye-catching 71% as of 10:50 a.m. ET Tue...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Pavel Kapysh / Shutterstock.com Occidental Petroleum (NYSE: OXY ) stock is rising on Tuesday after Warren Buffett’s Berkshire Hathaway (NYSE: BRK.A , BRK.B ) increased its stake in the ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kezar Life Sciences (NASDAQ: KZR ) stock is up an astounding 74% today after the biotechnology company reported positive results from its clinical trial regarding a treatment for the autoimmune disease Lupus. In a ...
Gainers: Agile Therapeutics (AGRX) +81%. Kezar Life Sciences (KZR) +75%. Decibel Therapeutics (DBTX) +21%. Sutro Biopharma (STRO) +16%. Bellerophon Therapeutics (BLPH) +11%. Losers: Scholar Rock (SRRK) -11%. NGM Biopharmaceuticals (NGM)...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...